Abstract P2-02-06: Her2-low ctcs in breast cancer: Pipeline for phenotypic driven, single-cell collection and molecular analysis

Paolo D’Amico(Ripamonti), Massimo Cristofanilli(Cornell University), Ami N. Shah(Northwestern University), Anthony K. Kang(Northwestern University), Lorenzo Gerratana(National Cancer Institute), Wenan Qiang(Northwestern University), Meilynn Shi(Northwestern University), Carolina Reduzzi(Cornell University), Amir Behdad(Beth Israel Deaconess Medical Center), Saya Jacob(University of Pennsylvania), Qiang Zhang(Northwestern University), Giuseppe Curigliano(European Institute of Oncology), Andrew A. Davis(Washington University in St. Louis), Youbin Zhang(Northwestern University)
Cancer Research
February 15, 2022
10.1158/1538-7445.sabcs21-p2-02-06
Cited by 0

Related Papers

3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k
Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
|Annals of Oncology|2015|1.8k
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
|The Lancet Oncology|2016|1.8k
Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
|New England Journal of Medicine|2015|1.6k
ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer
|Annals of Oncology|2021|1.4k